Insight | 08.07.2019

Regulation (EU) 2017/745: new provisions for manufacturing and supply of medical devices


Marketing & Communication
marketing@lcalex.it

Here is the first Alert by LCA Life Science team: an in-depth analysis of Regulation n. 2017/745 recent provisions to which, starting from now, companies operating in the Medical Devices sector will conform.

LCA’s Life Science team is ready to assist medical device manufacturers in this delicate transition phase, in order to adapt their management systems, their internal control procedures and their contract models to Regulation n. 2017/745 and to share with them all sector-related news.

Read here the Alert.

Equity Partner
Andrea Carreri

Marketing & Communication
marketing@lcalex.it

Life Sciences

Also in the Life Sciences industry, our dedicated team combines cross-departmental skills and expertise to support a wider range of clients. We work with entrepreneurs, institutions, investors and domestic and international funds operating in the Life Science and Healthcare fields, providing full multi-disciplinary assistance, based on the experience and the real and in-depth knowledge of the specific issues of this industry.
LINK

You might also be interested in

26.03.2025
The Legal 500 (EMEA) 2025 – LCA Studio Legale

New Legal 500 rankings released. LCA confirms the positive trend with achievements in both practice/industry and person ...

20.03.2025
Chambers Europe & Global 2025 – LCA Studio Legale

LCA strengthens its position in the Chambers and Partners rankings

04.02.2025
LCA with Dealfa in the acquisition of a patent portfolio from Akeso

LCA advised Dealfa on the acquisition of a patent portfolio in the medical device sector.